Pain Points and Prospects Coexist in China's Medical Big Data Industry

Release time:


Since the "Healthy China 2030" Planning Outline was released as a blueprint and action plan to promote the construction of a healthy China, China's medical and health industry is undergoing earth-shaking changes and innovations. In recent years, including new drug research and development, social medical insurance, health management, etc. In the field, a more complete system and new market rules are gradually taking shape.

At the same time, China's medical big data industry has also ushered in a large number of industry norms and policy opinions. In fact, the domestic medical big data industry is in the stage of rapid construction. The scale of the medical information market is increasing year by year, the project construction results have been implemented one after another, and a large number of capital and enterprise participants have poured into the market. With the gradual growth and penetration of the industry, it has significantly promoted the pace of production in many fields in China, including pharmaceutical research and development, public health monitoring, personal health management, medical diagnosis and treatment, and treatment, and other fields. However, compared with other industries boosted by Internet technology, the overall construction speed of China's medical big data industry is still slightly weak.

Throughout the history of the industry, the development of domestic medical big data can be traced back to the new round of medical reform in 2009, which designated the construction of medical information such as electronic medical records as a key task. So far, the industry has accumulated massive data for 10 years. In fact, the future development space of domestic medical big data is huge, especially in the era of the rise of domestic innovative drugs, the market demand is strong. However, due to the circulation and sharing of medical data and many other problems, even though the foundation of medical information construction has been laid for ten years, there are still one information isolated island after another, which hinders the development of the industry.

Three Difficulties in Data Collection

From the perspective of process, medical big data includes multiple links such as data output, data collection, data storage, data processing, data analysis and data application. Each link has a complete supply and demand scenario, and market participants jointly build a smooth industrial value chain. What is more special is that due to the simultaneous involvement of medical and Internet information security issues, multiple regulators are also staggered to exercise regulatory authority over the industry.

From the perspective of data sources and output links, hospitals, clinics and other medical institutions produce massive amounts of medical data every day, which is the most important producer of original data. However, due to the difficulty of breaking traditional concepts and the long-term lack of laws and regulations and market incentives and other factors, it is difficult for medical institutions to "merge and store" a large amount of data ". The first is the complex medical information system of medical institutions. For a long time, the development cost of the information system of domestic medical institutions is high, and the hospital systems are independent of each other, with different interfaces and different standards. The word "honeycomb coal" is useful in the industry to describe the data of various medical institutions, such as difficult to communicate and difficult to share.

Although as early as 2002, the Ministry of Health issued the "basic functional specifications of hospital information system" has clearly put forward the basic requirements that the commercial hospital information system must meet, but in reality, in the face of huge operating costs, few hospitals can meet this requirement.

Secondly, data gaps and data errors caused by various factors such as differences in various data standards, operational problems during entry, loss of stored data, etc., have also led to subsequent medical big data enterprises to carry out effective data processing and development work when facing medical data with uneven dimensions such as quality and particles.

It is gratifying that both the national regulators and the major medical institutions have begun to deeply realize this problem, and gradually set out to improve the situation from the scope. The state has issued a number of policies to support the development of medical big data:

At the same time, more and more medical and health institutions are not only aware of the great value of data, but also begin to gradually establish standardized data access standards and processes from within, or actively seek the cooperation of third-party enterprises to upgrade and transform the existing system. At present, many domestic medical and health institutions have taken the lead in the construction of this area, and some institutions have even passed the five-level evaluation of national medical and health information interconnection.

In the whole process of data collection, enterprises play a more important role here. Domestic enterprises mainly focus on data collection, storage, processing and analysis. According to the current development situation, the data collection market is more mature than other markets. Most of the relevant participants are software and hardware manufacturers, medical device or wearable device manufacturers, etc., and their enterprises are larger, and there are many listed companies. But for these enterprises, only from the original data collection work is faced with three difficulties:

1. Data collection is difficult

The medical field itself has strong professionalism and sensitivity, and the medical industry has always been highly regulated by the government, with high barriers to industry participation, and the interests of relevant parties are also complicated, which has extremely high requirements for the industry resources of enterprises. In addition, the lack of uniform standards and specifications for data output specifications and collection tools makes it difficult to grasp data quality, and companies often need to pay higher costs to obtain high-quality medical data.

2. High compliance risk for data collection

The professionalism and sensitivity of medical data are high, especially the privacy of user data involves the dual protection of ethics and regulations. Even hospitals don't know what kind of data can be shared and what the risks are after sharing data externally. Moreover, due to the long-term lag in the construction of industry laws and regulations, unclear data ownership and use rights, lack of management of data sharing, lack of access and quasi-export mechanisms for data applications, etc., some data have compliance problems.

3. Always face data security challenges

The large-scale application of the Internet has also brought a huge risk of public privacy data leakage. The current global network data security is severe, and the number of data leakage incidents continues to grow, and the harm caused by it is becoming more and more serious. In particular, big data has become the key target of network attacks because of its huge value and centralized storage management mode. Therefore, enterprises should not only ensure the security of their basic components, but also provide security for the data and applications running on them, as well as provide security protection for the data flow process in business applications. This puts forward extremely high requirements for the data security protection technology of enterprises.

Market Demand Promotes Rapid Development of Medical Big Data Industry

In a sense, the market incentive mechanism may be one of the most important factors to promote the construction of data interaction standards for upstream and downstream participants in the industrial chain. On the supply side, medical institutions also hope to convert the "sleeping" data accumulated over the years into value and obtain more operating profits. On the demand side, companies including pharmaceutical companies and insurance companies urgently need big data to enter the application scenario to reduce their own research and development costs or operating costs. Even doctors and experts hope to obtain follow-up data of patients after treatment to support their academic research.

Therefore, enterprises have a large number of market cooperation opportunities. For example, in some countries such as the United States and Japan, where the development of the industry is relatively mature, the business model of many start-up companies is: on the one hand, to provide medical institutions with cheaper services, so as to continuously collect and accumulate data; On the other hand, sell the data to other start-up companies focusing on the technology application level or provide it to other enterprises with data application scenarios after processing and analysis, the biggest demand side of this chain is the major pharmaceutical companies.

A considerable number of domestic enterprises have collected a large amount of data by building a complete product background, and some enterprises will do some transformation work for some redundant unstructured data. The industry has recently discussed topics such as how to accumulate data and gradually turn precipitation data into industrial application landing of data. It also shows that the work of enterprises in data collection is becoming more and more smooth.

Safety specification is the foundation of industry development

As for compliance issues, counting the development trajectory of any industry, the construction of the legal and regulatory system is inevitably lagging behind. The "National Health and Medical Big Data Standards, Safety and Service Management Measures (Trial)" has detailed provisions. However, the current "measures" are still laws and regulations with heavy guiding significance, and there is still a lack of specific operation details, specifications and process guidance ".

Therefore, at present, hospitals and enterprises have concerns. Even in terms of ownership, some companies have put forward the concept of "data barrier", believing that these medical big data are the core assets of the company. Therefore, to completely solve this problem, we need the constant balance and game between "privacy protection" and "industrial development. From the current actual situation of the industry, private enterprises obtain data through scientific research cooperation with medical institutions.

"National team" enterprises obtain medical data of a place through government-led cooperation authorization. For example, CLP data is led by the government and authorized to aggregate and manage hospital data of a region. From this level, the "national team" of CLP data will be more reliable in terms of data compliance and security.

"National team" is the main force to solve the problem of medical data

At present, the current construction of the domestic medical big data industry is still in the early stage. Fortunately, with the efforts of the state and enterprises, China's medical big data industry is developing rapidly.

In the first half of 2017, within three months, the "national team" of the medical big data industry-China Health and Medical Big Data Industry Development Group Corporation, China Health and Medical Big Data Technology Development Group Corporation, and China Health and Medical Big Data Co., Ltd. Announced preparations for the establishment, the pattern of the three major groups was quickly established.

The three major groups are led by the former National Health and Family Planning Commission, with state-owned capital as the mainstay, behind which there are three major telecom operators, several major state-owned banks and other state-owned enterprises, which means that central enterprises have organized groups to enter the health care big data industry.

At the same time, five medical and health big data regional centers located in Shandong, Jiangsu, Guizhou, Fujian, Shandong and Anhui have been established one after another. They respectively undertake national pilot projects such as national health and medical big data center, regional center, application development center and industrial park construction, and continue to deepen their responsibilities to promote the overall construction of the industry and the cultivation of the industry ecology, actively promote market cooperation or introduce private enterprises to establish joint ventures.

Jin Xiaotao, former deputy director of the National Health and Family Planning Commission and president of the China Health Information Technology and Health Medical Big Data Society, once emphasized that the operating principle of the medical data "national team" is "government-led and market-operated". Under the supervision of the big data office, the "national team" will undertake the investment and operation of the national health care big data center and industrial park. With the goal of ensuring the security of health care big data, invest in key enterprises in the industry and break through core technologies; use financial means to promote the incubation and cultivation of the health industry, build a health care big data industry ecosystem, and promote the construction of national basic health care big data.

The establishment of "three major groups and five regional centers" is equivalent to starting to excavate the "gold mine" of medical data from the national level ".

Big data empowers all kinds of medical enterprises

How to process the "gold mine" into products after it is excavated requires the participation of enterprises and capital, and provides assistance for the development of medical enterprises.

Recently, in the context of the outbreak, Wave Health announced the completion of a round of 0.1 billion yuan financing, strengthen data value-added service capabilities and Internet service products, with more regional and large medical institutions to accelerate the creation of personal life cycle health management platform services. This is really not easy, and it also proves that capital is optimistic about the medical big data industry. Because this kind of data and technology empowerment is to see the effect, recently, Jingtai Technology teamed up with the pharmaceutical industry released important progress, chloroquine or into the new crown pneumonia broken drug. This is a demonstration of the use of big data and artificial intelligence to accelerate the development of new drugs.

Another example is the cooperation of CLP data to the Medical Association, Senyi Intelligence, and Pharmaceutical Mingkang. As the "national team" for the development of the health care big data industry, CLP Data, how to give full play to the advantages of each shareholder and cultivate the core capabilities of the national health care big data industry development group for safety and intelligence is the top priority.

In 2018, CLP Data participated in the D round of financing of the Medical Association, with a total financing amount of 1 billion yuan. At that time, the medical association had already been deeply involved in the doctor link, but the possibility of expanding to both sides, whether to the patient side or the pharmaceutical factory side, was very low. If there was a strategic investment in CLP data and cooperation with CLP data, the medical association could expand horizontally, and the pattern was opened at once.

Similarly, the core business of Senyi Intelligence, established in April 2016, is to solve the pain points of medical big data, convert low-value data into high-quality data through data governance, and promote data-driven artificial intelligence applications for medical research, medical management, and patient services. As a technology company, Senyi Intelligence is a research platform, natural language word segmentation and data structuring. After working with CLP Data, it was transformed into a data service company. After entering the hospital through the scientific research platform, the data of CLP can be directly used to make active analysis to the pharmaceutical factory. It went from a technology company to an operational company.

In addition, it is worth noting that CLP data and drug Mingkang strong combination, CLP medicine came into being. It relies on the national health care big data service platform and the national health care big data security platform built by CLP data, and integrates the professional capabilities and rich experience of WuXi AppTec in new drug research and development and the big health industry, providing partners with integrated health care big data analysis products and solutions for the whole industry chain from drug research and development, post-marketing drug efficacy evaluation to circulation and sales.

In fact, in the medical industry, similar to zero krypton technology, medical cloud, Taimei Medical began to use medical big data to do services very early. For example, as a provider of artificial intelligence and medical big data solutions, Zero Krypton Technology will be established in 2014. With their core technologies and capabilities in medical big data integration, processing and analysis, they will provide overall medical big data solutions for society and industries, government departments, and all levels. Medical institutions, domestic and foreign medical device manufacturers, pharmaceutical companies, etc, as well as AI-assisted decision-making system, patient process management, hospital public opinion monitoring and brand building, pharmaceutical research and development, insurance control fees and other integrated services. The company's 2018 round D financing has reached 1 billion yuan.


On the whole, although there are still many problems in the domestic health care big data industry and various development obstacles caused by the particularity of the industry itself, in the long run, there is a huge room for imagination in the development of this industry. Under the background of healthy China becoming a national strategy, the application prospects in various related fields are broad. In the future, with the deepening of industry-related services, humans may be able to predict the outbreak of epidemic diseases and reduce medical costs. Patients will also enjoy more convenient services. Traditional public health management and medical models are bound to usher in disruptive changes.

From The Arterial Network


Quickly find what you need to know

  • All
  • Product Management
  • News
  • Introduction
  • Enterprise outlets
  • FAQ
  • Enterprise Video
  • Enterprise Atlas